{"ticker": {"uuid": "4591b1df-eabb-48a3-b1de-ba8e31e97f8f", "symbol": "EWTX", "name": "Edgewise Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQenpLb0cteU5ENHpYb28xckdncGZhZFlhN25aWVdLMVQtd29ZSFo2ZGtIeTFPTk4tU0tHdkU3QU1rUV91LTFJRHJjckpEb1FlMEM5UHNQMURkZlF0T1FiU1EyVUV5aFo0NHNxbDBJaV9hWmY5UWdkWGVMaWxLRWl5RlRIUXpZcmowMlVKenlqNldrNFVIQUFUM3JvbU5mTDRMZnc2Q1BXNmRFWWVoUENHc1pYUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T14:04:06+00:00", "published_display": "13 Jul 2026 14:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Edgewise Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNc3RoeVNhUGhMcWVqM0tIMHVra0ktQUsyR2NTS2o1WkdtSERrd21MekkzRFhHSVRpWTA2ZTEzRWx0MVdhZ3JOOEpPVExROHNjWW9wMF9FQTM4WGM3aXB3amxFNFIwclMtM3Z3VnNtUFFZQWN3ZGlENHVuQkJpbE1XQ0ZIbGg4TkVYb29kMmlNUGFxVUZweC0zaFZSV2RNV3FuOVlJbVlkd0M1RjVUajVvaXpkVHk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:37:42+00:00", "published_display": "13 Jul 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Muscular dystrophy drug sevasemten drives Servier\u2019s $2.65B Edgewise buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQWZQYkl2eGZ3MXNaM2VpdWxJWThQT3BlRkdUU014ZkhSTU0xS1NDLWRPWE1EeXg2MVBCSnphZ1NURU9kYlBhSmFBbUZpZG5UMlJkRGk5OEd6WWYtc3Z6MTdpazE1NmZNZm5rcUNsUGR0TmU1S0JhNjA2N1VmQUctUC1fcWJ3TDF0ZzVqRk1ET3lhelMzbG9kZk81UkhZRVc2ZVZTV1RtZzNRNG8yZ2t4MkpOTGlrOURBdFJBMmt4dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/servier-completes-acquisition-edgewise-therapeutics-123000557.html", "source_name": "CNW Group", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-completes-sale-sevasemten-123000072.html", "source_name": "PR Newswire", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Edgewise banks $1.55B upfront, pivots fully to heart drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNXNnenF3VEd3TlJ3MEltcXMxRW90MTFKYU5RMG11TndRTnlQMm9SNU9lck4wQ3lEbFNuVU9vMmR3VGpjXzZVSll0ZGdCRU9BUXNfeTBxeGVjcHZYY0VxY3lqVXh4ekpuVGdDbTNXZ3Fyb05RRFBJVmFRalQyWjJLMmYyaks2TUcwaFJJWFZ2Z1cybmpQTlNmVnRudjlFdS1fM2dnTXFuVFhmM19Lc2tLb21BelBXTmdhTTVodQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZGV1ZWxvVWNaZE5sbmNFbC0wZmF5Q3VXX041Y1lSNFRyT25GZV9jTzNCUDNrWTdhNzFMRkJFVUZWd3MzaDl3X05HblpwZFlMQXlwZXhWZGpoVF9QUXlYd2RnTHhMdEs1RldNcVhwMHpxNUhFb0dlVnJQWURja2M3aUN2d0RXeDdXN25raU14QkJoM0FvdU5HS3FPWnJCWGdJajZwWjRTWTJDZ1RxZEtiTjF2aFplR08ta0lGQVBMa0JUTGVTbnpiS1Zn?oc=5", "source_name": "Trefis", "published_at": "2026-07-10T11:46:05+00:00", "published_display": "10 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-apos-edg-7500-151702678.html", "source_name": "MT Newswires", "published_at": "2026-07-09T15:17:02+00:00", "published_display": "09 Jul 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Edgewise Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-initiates-edgewise-therapeutics-outperform-121908547.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:19:08+00:00", "published_display": "09 Jul 2026 12:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics(EWTX.US) Officer Sells US$7.88 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOb2Z2U3FGOHQyS2x6X2o2bmNWMHc4S3RBWEUwbllIeW1qWGgyRFI3anVXOVlPUUREb0djWjVOQl9yZzlnQzliSnhjeG9aUkpkeV9jeDB1SHVJN0dxMWNWTVE4U0YteUxITE5xTTRBZklWMXV2XzdsNEdFNGxCaURmVWpCcGNNS0JDU2pVYW1hcFR6QmJYZzVDejJYMTRWSThmamVycTBn?oc=5", "source_name": "Moomoo", "published_at": "2026-07-02T22:53:12+00:00", "published_display": "02 Jul 2026 22:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQamhjU2tveVdkZzJreERDT2NLb3ZyR0tQTTE3em0yMzJNNGlTbnJ0cHI3SHRLeHdkdWM5QU00VzcxQ1pteGpGWkJlUUw4MU5wanVDMktDZjNySGlPRDJFZEJPdHRkcXEzN3VWVnZ4Rk4taTZqUUtUQWY2WG5IaVAtLXp6WHB0cEEwdE9aMkpJalF5NW5DNE5iSXpuX2ZSUFJRbUFUeDIyVGxRXzJxM3drRDhwcGhNT2NHOVNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Edgewise Therapeutics(EWTX.US) Director Proposes to Sell 8.13 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNcDkyMS1uWGhESDFKZFgwUGVoYzRzc3lKaEtKNkJiOHZrdTFoY3JuTElReURvVktLU012OFg1U3B0R2I4ZVRBT1phQ0RibmNwSDlJWjlrVV9mVC1HUFZJT3NLT1ZWNE9WblBURXpaeHc2SlZNRXpmOFV0eDFDMlRhVkc4WnBDN2dSOThiZzNSVzZJb2tDT3gwd3BreE12SXRfWE41T3A1Tlo0WkE0?oc=5", "source_name": "Moomoo", "published_at": "2026-07-01T20:56:25+00:00", "published_display": "01 Jul 2026 20:56", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Edgewise Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlRmb2dPam8tbVBVNFJ0aXYyVWY0d1RuRktuN0V5emU5dVZDZ3Z3eVFNVTJUMHB5Q2tybUtuZ3pJX2FzN01GUDRTVExUdmdmRjlNa0hwSVBrRU1nSk5OZkhoclktNHN0alFja1E3OEROeHNKRzJsb1RQN2htRGFlX290UkF2ZHVTQ2tONEJ4YkpnX21RSlR0TmgxVDhMWnVmS2Ytcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT3BGVVp4TnFTUEJDdUdMRVF3S0pXSldYaEtWZmR2RTBYcmREbFFEYktSU211UE5CeERBbkctc3UzZzVYbW1vRjNsLXphS2ZtNi1JSk5tdU5veGxJZDFybjVnTXhadGhwREZ6c0FYeHRfbTFrd05jVi1VUS0wUmRYMzU3NXdvOXZ6eHl1V055U1piNWlldm8ydnM4NVN3Yy00TDdrZ1dXQV9Uc2l3dU92MVJpT1JjQ2NpLTNz?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise lures 2 new employees with 16,500 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOeVk1SmJ3M2l2RTlBRUgzNEExV3pwN21XRzBuOWJ3SlYteXNRMnYxcUp5TmMwSXdZZ01PNG83WUpjWXFpN2JmSXpTclJOX2lVQXVTcmNrQV9zZDlNRll6bE84UHlDMDNhVGFGM0dOYjhkcDNNY1BjUERuMW8yaldzTXlZNDZVUlZEM1M3YkpIbVdxZENRMF9YN1hYaXBXWTZNZzg3RTdOSE5lWVc4YmVHSXlNYXUzbmxNMzNsVjhIYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRW5ZcVlkaVVIelhJN2UzVUR5bzctZUVpeWdpSng5dzhxbHUyN0NTeUF1YkhSRVh1eTZkQjNVYzdPZzJFZlNnUzJtM0hoaWxOU1NHQWJLSEpsZ1lyTElhejBnUlk2NjN2TGcxWnRtMV9SRjktNWwyZjhsTEVLNHE0ajFSaFJ5YnplQlRadFpDTDRZaGh5UHFjc0s3Z1AzUDJGc0E?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTHhHeERFb2w5Y1dSaTdhcGlyajkwX0hTS1hzNVpMaWw2YVN1MDNWTXk0XzY2eW1VZlVIU3ZkYnpGbUhBNlA4WllDV214R19vX0hRLUFyaDlZUklpN0czdWNGaDBTQTBDV1NHVXJwTUdxdW8xVU5xTVJuN0QzdTc1b1g2YzRmVHlnLWN5enZFT19YbURkSHZCVWhkUTVYQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQdzlwazRuQ19XUVNQS2Y3WFVodjdVODAtLUcwRVlNNjhoMjJwU3FFa3VSS0ZHNlpreEdpOTBvTmVnZHNBNTYtaWlGOFJPMUFrSmFJbXhsRzVrZHRIbm1FV2dwNFdmYXB0R05qZFFORUl1ZDRXY2RGYnpyQjU3WFRkck5KZ3Q0cnRGWEl1V3lhX3N0TzQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-remains-compelling-cardiology-150254298.html", "source_name": "MT Newswires", "published_at": "2026-06-17T15:02:54+00:00", "published_display": "17 Jun 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-price-target-edgewise-104255500.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:42:55+00:00", "published_display": "17 Jun 2026 10:42", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMlNMS0hkU3BkWGY0ZEdleFdEOEROTUtDOHBBOXlYZDUxVWlHV252Q3EzSXpfWVo5Q0pJdEl5S2pBU1RBV3VqR3hoSGVTQUxudHFHdE1EMndaNWhGZkVrVEZ2STlkdml1TnVwb2YtSnRGUDRuaGwzajhFTWZOTm1TQlEyRElQUVNlMXlNZjRGcUQyQVJGSkh3dW1RSlBNclBsUHVLMmtzNGRJQjBENlB1TmNROUo2eVpCWmRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxON182TkxXVjJUVF9QUmRZQndEMUtXS1UzNGdQX2dmX3BuMVBPYVJGWFhvRWk3MzBWUE1UZks2ekM2VzZJYnBMMV9JUjBmYU9pdUdycWVuMWE0RWJLZ3N2Wjcwb0ZjMkUyc1JrS3dGRE0zVVJLcHJEanVqSFlIemRSZnZPdzlPQkdGS3lCTXB0Nl80TEZjRU5MSFQ4NFBXM3VYeGk5dTRaZWlHMW05dDVfbWVoWEhzZ3NRNUlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxPcUZwZmJHUVJOd2ZEX3BOVjZCUk9XMmhTZ3R5aE96U3M3TDNjU1FPRThFbTNHd2x0eHF0SnZWSzE4S2ozR3FidFRvSWplSlBRczc5RjBud2F2QTFWRlhvbmNHajFJNWdCUFoxZTY0MTRoTExjS3VpWGRKTU1RTVNRSW43eWk4TFJfQ0UxQ3NJQ3EzX1AtemtjR1Y0SmdBZWo4aVdFbGpseWZmZTRfTi1BOEhfWC15cFljR2ZJQmx6ZXZ5d3FuSHBNNWxGWnRoQjgzcVlJSGllLV9VRXJtM2hSS01VNi1GQzhNNUdQWDJFQ2tLek03Ylo3MXB3bXlGSzFMYi13bUNISzN4dVhzN3prTllOSW4tbFc2Z1l3UWVqTW9KXzJKWk5Fby1pZUxBMko5b3BiTVlBbVhZbFNfV0lSN1VhbmJxMlVWNW9MaQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNaDE1X3RtSGVvXzlkT1l5WkxjdFpVNGJIWlA4alhqZDVpX2I0MDVUbVpHSVBUZGhvUDNoSXlVNVlfdUhaOTZFcmR3d0VyeENEQ0liZTJveU9GRXFQTGJHdWJIeE5WeE1wTXBGNi15LW9TX3VLWkJfaTU0eG9xdlU1TTlQeWVKdFBTWDgzdkdxZUpXT0ZFTXZPZXFwd1ZPdEFWclNZTXFxcGZaTHFKZ0Z1VVdNS1l4UVNhbHJDLWY1cEZqQQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaDJWWUpKakk4NE9YRmJFUjY3ZkNHM2J1X055eUxqeUtUSnVoOWhNbWpvTkNKbm9GQ0U4NE1DbThFUU8wYmNrM0tNbkdRR0FpMHVfM2tKOXhuOExNQU1ZQkxrQlMybGpsRDJhR0JWTkNfeDdueW5KekZFYVM3cXB4a2xHT28zbDNXcGY5M1k5UGhrSjd3UzczSzY5VW9qUU9YWExHRVBHUkNjRGllN05EdmJLZWFfeHZ6REhV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNM2llTHRJeGxfMy1jMGdvaWtTaS0wamY0NC1nalpURGdFQWFfVm1SM3JhdlB1ZVFUc3VGQlUzaWRTQjBXbi1UV24wOXI2S2VJR19LdklvVW9YZEprY2JHU0RVdUtGZm5iSG5neDNoTjFYdWxCTTBzTEJVVDl6WVc4VS1UQ0toQXpxbTF0TGlScUVRS2kteVFHaUR0UmR2S1BOeVRZNGhMTXllRDBkT0R6SDBFQXRKQU9YYUlvN2xBbURLdUVlV1JWR0plNG9hdU52WW02bTlHOThMcFE3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLTRDY3lyc2kzV2Z6VnhmYlhSbkNFVUhQSVVSWmRUM0xOWXBkNWplMmNub2tPY3NzeDZoZXN1eVZUTnJaUU9WNW5qMVRhUnFqcXVLZzVWZUtyTmMxZFN6U1dKN0dVY0N1T0VQRGowUk9lbjZfTUdTTkVCV1d2ZWFJOVRWZHltM2RWQV9oVXByTzRNcmtDNmhhc2ZQZ2ROYjJlNksyODZ0V3YwTWFzeUdkSVZ5bUZVRUc4WkhOY2RYNA?oc=5", "source_name": "TradingView", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQaC1OZW5wb09uaEl4M0V6azVLUURNdUYybWFOTjVETUU4Q3VOTmtITWNCa3k0c0dxa1RkLWFYa2EtdGZrNmMyem9hZnZZMkZxczJxOFVMUzJYOU1KWi0yX2ZnY0lKaTRLU0pELUpqbzBNT1lpYjFKeEtVMXAyUGQyMGJLcnRXQUtTcmFMaW5sb05FT2NmNWwxVDVSTWNnLUJxWGdBWlhQMjQ4X196SklwaA?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EWTX Stock Hits Record High \u2013 Why Servier Is Shelling Out $2.65B For Edgewise\u2019s Muscular Dystrophy Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNdW13cWI3aWtGeFN1ZkYxSUF2TU1ScGNCMEY5RDlnd3dyRjJIT0FjeVRTNGstWUFPT1lSMlNzTnFhQ0JiM2lKbWt0VlFuQlhSQl9HN0VnUzNPU1NiV1hCc3htdW5xNUZZVEVGMWNXUHNZczBSaXJQbFl4SXI0LUpPXzFQd2V4V0ZCQW5JNHdGeDhKMHNRMHdMN21NTzlJWHQwY281U3RreF8ySEFmcC1NSA?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdUNKRVpMMldfSXBFVjNDaHZ1QzU1c3ZmSjVYQl9zV1Y4aTZGeExTbWROU0dTNjZuS2ZiWU1DQUs5X3lBcEhiU0Fvc2liMkREdmtOY2VsaFpZb09pV3h2d2NxelBEQUZ4eTM3T2d5MnhfMmtNdGFVVVBXZ2J5b3hiMUJVUmYwUHVOUmJMcTBzalhwdDdtbFRPcGIwbXhMVUVtakpSSG5sWHdHWDEzaEd5YVhFZmc5Q3BpU0w5QkwySHNPcUd4NWZTalFB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Muscular dystrophy sale to bring Edgewise $1.55B for heart drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaDZJajFETm1CNkd6M0lJZjdzak0xS0JoSXFGN0RndUZVVy05VGxEa1o2R0wxTEVSWGVMY245akpVdHg2VWF0cWJhSVM4TzI3MFFZclJpazVaNjRZRUNsdG9UaUpudlA4Uk9KNEpLUS05MUYxbndHMlozVUtSU3lQNm9xU2tIYVI4ZlpaTXFFWml6Nld3RTJ3OGRIbDJBZ21YV3I4aURUNjhXczRqWnZ5MTk2UnVFWkRXSHMwTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQNElUSWVkT0lKNkN0Zkk3dDltanFTMTdBeS1BTDVkeG1Xb3c5elpKOWRaVGlhZ25YTFNKOEU0RXhWZGhrN2ZEUXoyWHdhaFVPRWl5N2t3OS1EZEt0blh0VU9qbTJfdWhneFVXX3hVZHlsTmlObnFDQkRWR3R3NzBoWnhqdHpEWEEyM05JdWxPRWtxSVFZLVpWdG1DZUN4Y2pfUTRyakxvOHpsQ1BqQzNXZWw0U24?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNck9HQ3o3S1lyZ0IyVl9CRWRtVEhzdXhrbjFxMFVTVHI0MHI3RGJOQVB3LUFpay1vTVZjTHhWZERWa1UyeHJCOWE3dEZQeC1HVXgwLUxXNmZTN0M1dmppdy1sMU5uZTMxZGFaMm1FRG1KMWpWb1hraldraTNOVFpGQlhfLVlyX3pXTGxBbHRLMnNRNlBzOW50b1VrQXdadlRhc2NOMks3UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome \u2013 So, Why Are Analysts Bullish On Edgewise Therapeutics?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQLVpXdWp1VUhQdTJwbjB3Z2l5NlBtQXZ0Rk1IYkcwMlZGeDVIVXVxNlY4NjA0alJuRTNLZEdVVFQ2bFA5SlkxUmpWWXJHTW1XeUlZbC1aZnFsdG5KUW1aT1JlcFRHY3NrRWNZT1g0WkhKWEpfc2NMRDRkX3llRXhIT2ttbmYyZ0kwT18wc0VacnhldWZNdzQwTUlfUW56VVhvSnpFcFlfNm9zX29TZ2hj?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Edgewise Therapeutics Stock Topped the Market on Tuesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOVHJSV1RRc2hSaURqbWlBWS16NVlnWjZzWDFCNHV2OUowMjNxVk5reS1qY1ZMMW44V2RRTVVKcndmNlQzOTVTRk85ZVI2NDFkLUZtQXJkSGk5dWRGbWR3RE13cVhodzVvaWN3MUJsb1BSaHBOT21zbzg0dWN2ZUhNUFd4d0dWOG5ZREFuVUd5NXFGek56TGVv?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxOeVZfa01UU1p1b0VsaXBtQ0tnSzFTenZlQkI0TlVXMGxmVE90QWVuVG45cTFnLUNwWkY4RGtPdHl0YkIyREwwZGJnN0F4cnFRZFc1S0lPbWZyREk3M2szT1hEWVJtaXJjSVRWVGJtS2NJbXQwSG9LU3FiVWpoZk9YNVNCQlpuRUR6VXBjSUpxUURxNE5ES0c1M3k5LWhEMzRIUHNuVmxGS20wT1h6STVUTEJXdDk0dUVCeW0wdFk2bXZuX0RVZDZuX2J3VjdiUzhiQzdfUjdBR19LdUxIMWZuU2sxYk1YR2hqQjQ1NVdnc1pibVJJOUZWc1kyN1ZpX1ktbmRYMVRPREFiQmtRVm1qSmxMVFN4NlhSM1lqTzRTNUd2WE1oQ240dERGbjFHWEVHUjNXRG1Wbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities \u2013 And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNYnJyUDNLdWZKWk5YeUgyWXhmQnRzbmVqbFl4dVp4MnRyYTM4VTcyYndBRjRDR05SZVFzazlMMXlfWnN3Y3pwVmQ3dVd4bkhBR2NMMHlidWJLVFB4czU2OUx2V2ZtS2YxRDQ5YXprVGt3SFo1Yk85UUlwaktpRUNyVFZuYzU?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease \u2014 Wall Street Eyes A Potential Standout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYzV0VTZCU25rUzVxeXVnWDF5a1F5MjNRUjNSRWg4UkdFVzE2a0tvYWRhcUZBZEhBZGgycjY0RTlTM21pWktIc2otaXhlTTlWeEpOY3NNanlLZHg0QlYtUVJGNEVDZjhMMW5IUkpTMkdodnQ0WDlGeng0dEYtaXFSZjhhb3pXeFdIR3pXUUh1U2daTUphVzFwWFpudGhMR2NXNmotcTFUeWZ6QlZHSDBITFB4NnZ4Q2lpYlllQkpnQ3FtYlR5d05TRE9Pcnp1TXhBZi1NYUNFU21JQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQenpLb0cteU5ENHpYb28xckdncGZhZFlhN25aWVdLMVQtd29ZSFo2ZGtIeTFPTk4tU0tHdkU3QU1rUV91LTFJRHJjckpEb1FlMEM5UHNQMURkZlF0T1FiU1EyVUV5aFo0NHNxbDBJaV9hWmY5UWdkWGVMaWxLRWl5RlRIUXpZcmowMlVKenlqNldrNFVIQUFUM3JvbU5mTDRMZnc2Q1BXNmRFWWVoUENHc1pYUQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T14:04:06+00:00", "published_display": "13 Jul 2026 14:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Edgewise Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNc3RoeVNhUGhMcWVqM0tIMHVra0ktQUsyR2NTS2o1WkdtSERrd21MekkzRFhHSVRpWTA2ZTEzRWx0MVdhZ3JOOEpPVExROHNjWW9wMF9FQTM4WGM3aXB3amxFNFIwclMtM3Z3VnNtUFFZQWN3ZGlENHVuQkJpbE1XQ0ZIbGg4TkVYb29kMmlNUGFxVUZweC0zaFZSV2RNV3FuOVlJbVlkd0M1RjVUajVvaXpkVHk?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:37:42+00:00", "published_display": "13 Jul 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Muscular dystrophy drug sevasemten drives Servier\u2019s $2.65B Edgewise buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQWZQYkl2eGZ3MXNaM2VpdWxJWThQT3BlRkdUU014ZkhSTU0xS1NDLWRPWE1EeXg2MVBCSnphZ1NURU9kYlBhSmFBbUZpZG5UMlJkRGk5OEd6WWYtc3Z6MTdpazE1NmZNZm5rcUNsUGR0TmU1S0JhNjA2N1VmQUctUC1fcWJ3TDF0ZzVqRk1ET3lhelMzbG9kZk81UkhZRVc2ZVZTV1RtZzNRNG8yZ2t4MkpOTGlrOURBdFJBMmt4dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/servier-completes-acquisition-edgewise-therapeutics-123000557.html", "source_name": "CNW Group", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-completes-sale-sevasemten-123000072.html", "source_name": "PR Newswire", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Edgewise banks $1.55B upfront, pivots fully to heart drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNNXNnenF3VEd3TlJ3MEltcXMxRW90MTFKYU5RMG11TndRTnlQMm9SNU9lck4wQ3lEbFNuVU9vMmR3VGpjXzZVSll0ZGdCRU9BUXNfeTBxeGVjcHZYY0VxY3lqVXh4ekpuVGdDbTNXZ3Fyb05RRFBJVmFRalQyWjJLMmYyaks2TUcwaFJJWFZ2Z1cybmpQTlNmVnRudjlFdS1fM2dnTXFuVFhmM19Lc2tLb21BelBXTmdhTTVodQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T12:30:00+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZGV1ZWxvVWNaZE5sbmNFbC0wZmF5Q3VXX041Y1lSNFRyT25GZV9jTzNCUDNrWTdhNzFMRkJFVUZWd3MzaDl3X05HblpwZFlMQXlwZXhWZGpoVF9QUXlYd2RnTHhMdEs1RldNcVhwMHpxNUhFb0dlVnJQWURja2M3aUN2d0RXeDdXN25raU14QkJoM0FvdU5HS3FPWnJCWGdJajZwWjRTWTJDZ1RxZEtiTjF2aFplR08ta0lGQVBMa0JUTGVTbnpiS1Zn?oc=5", "source_name": "Trefis", "published_at": "2026-07-10T11:46:05+00:00", "published_display": "10 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-apos-edg-7500-151702678.html", "source_name": "MT Newswires", "published_at": "2026-07-09T15:17:02+00:00", "published_display": "09 Jul 2026 15:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Edgewise Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-initiates-edgewise-therapeutics-outperform-121908547.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:19:08+00:00", "published_display": "09 Jul 2026 12:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics(EWTX.US) Officer Sells US$7.88 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOb2Z2U3FGOHQyS2x6X2o2bmNWMHc4S3RBWEUwbllIeW1qWGgyRFI3anVXOVlPUUREb0djWjVOQl9yZzlnQzliSnhjeG9aUkpkeV9jeDB1SHVJN0dxMWNWTVE4U0YteUxITE5xTTRBZklWMXV2XzdsNEdFNGxCaURmVWpCcGNNS0JDU2pVYW1hcFR6QmJYZzVDejJYMTRWSThmamVycTBn?oc=5", "source_name": "Moomoo", "published_at": "2026-07-02T22:53:12+00:00", "published_display": "02 Jul 2026 22:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQamhjU2tveVdkZzJreERDT2NLb3ZyR0tQTTE3em0yMzJNNGlTbnJ0cHI3SHRLeHdkdWM5QU00VzcxQ1pteGpGWkJlUUw4MU5wanVDMktDZjNySGlPRDJFZEJPdHRkcXEzN3VWVnZ4Rk4taTZqUUtUQWY2WG5IaVAtLXp6WHB0cEEwdE9aMkpJalF5NW5DNE5iSXpuX2ZSUFJRbUFUeDIyVGxRXzJxM3drRDhwcGhNT2NHOVNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Edgewise Therapeutics(EWTX.US) Director Proposes to Sell 8.13 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNcDkyMS1uWGhESDFKZFgwUGVoYzRzc3lKaEtKNkJiOHZrdTFoY3JuTElReURvVktLU012OFg1U3B0R2I4ZVRBT1phQ0RibmNwSDlJWjlrVV9mVC1HUFZJT3NLT1ZWNE9WblBURXpaeHc2SlZNRXpmOFV0eDFDMlRhVkc4WnBDN2dSOThiZzNSVzZJb2tDT3gwd3BreE12SXRfWE41T3A1Tlo0WkE0?oc=5", "source_name": "Moomoo", "published_at": "2026-07-01T20:56:25+00:00", "published_display": "01 Jul 2026 20:56", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Edgewise Therapeutics, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlRmb2dPam8tbVBVNFJ0aXYyVWY0d1RuRktuN0V5emU5dVZDZ3Z3eVFNVTJUMHB5Q2tybUtuZ3pJX2FzN01GUDRTVExUdmdmRjlNa0hwSVBrRU1nSk5OZkhoclktNHN0alFja1E3OEROeHNKRzJsb1RQN2htRGFlX290UkF2ZHVTQ2tONEJ4YkpnX21RSlR0TmgxVDhMWnVmS2Ytcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT3BGVVp4TnFTUEJDdUdMRVF3S0pXSldYaEtWZmR2RTBYcmREbFFEYktSU211UE5CeERBbkctc3UzZzVYbW1vRjNsLXphS2ZtNi1JSk5tdU5veGxJZDFybjVnTXhadGhwREZ6c0FYeHRfbTFrd05jVi1VUS0wUmRYMzU3NXdvOXZ6eHl1V055U1piNWlldm8ydnM4NVN3Yy00TDdrZ1dXQV9Uc2l3dU92MVJpT1JjQ2NpLTNz?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise lures 2 new employees with 16,500 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOeVk1SmJ3M2l2RTlBRUgzNEExV3pwN21XRzBuOWJ3SlYteXNRMnYxcUp5TmMwSXdZZ01PNG83WUpjWXFpN2JmSXpTclJOX2lVQXVTcmNrQV9zZDlNRll6bE84UHlDMDNhVGFGM0dOYjhkcDNNY1BjUERuMW8yaldzTXlZNDZVUlZEM1M3YkpIbVdxZENRMF9YN1hYaXBXWTZNZzg3RTdOSE5lWVc4YmVHSXlNYXUzbmxNMzNsVjhIYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNRW5ZcVlkaVVIelhJN2UzVUR5bzctZUVpeWdpSng5dzhxbHUyN0NTeUF1YkhSRVh1eTZkQjNVYzdPZzJFZlNnUzJtM0hoaWxOU1NHQWJLSEpsZ1lyTElhejBnUlk2NjN2TGcxWnRtMV9SRjktNWwyZjhsTEVLNHE0ajFSaFJ5YnplQlRadFpDTDRZaGh5UHFjc0s3Z1AzUDJGc0E?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTHhHeERFb2w5Y1dSaTdhcGlyajkwX0hTS1hzNVpMaWw2YVN1MDNWTXk0XzY2eW1VZlVIU3ZkYnpGbUhBNlA4WllDV214R19vX0hRLUFyaDlZUklpN0czdWNGaDBTQTBDV1NHVXJwTUdxdW8xVU5xTVJuN0QzdTc1b1g2YzRmVHlnLWN5enZFT19YbURkSHZCVWhkUTVYQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQdzlwazRuQ19XUVNQS2Y3WFVodjdVODAtLUcwRVlNNjhoMjJwU3FFa3VSS0ZHNlpreEdpOTBvTmVnZHNBNTYtaWlGOFJPMUFrSmFJbXhsRzVrZHRIbm1FV2dwNFdmYXB0R05qZFFORUl1ZDRXY2RGYnpyQjU3WFRkck5KZ3Q0cnRGWEl1V3lhX3N0TzQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/edgewise-therapeutics-remains-compelling-cardiology-150254298.html", "source_name": "MT Newswires", "published_at": "2026-06-17T15:02:54+00:00", "published_display": "17 Jun 2026 15:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-price-target-edgewise-104255500.html", "source_name": "MT Newswires", "published_at": "2026-06-17T10:42:55+00:00", "published_display": "17 Jun 2026 10:42", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMlNMS0hkU3BkWGY0ZEdleFdEOEROTUtDOHBBOXlYZDUxVWlHV252Q3EzSXpfWVo5Q0pJdEl5S2pBU1RBV3VqR3hoSGVTQUxudHFHdE1EMndaNWhGZkVrVEZ2STlkdml1TnVwb2YtSnRGUDRuaGwzajhFTWZOTm1TQlEyRElQUVNlMXlNZjRGcUQyQVJGSkh3dW1RSlBNclBsUHVLMmtzNGRJQjBENlB1TmNROUo2eVpCWmRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxON182TkxXVjJUVF9QUmRZQndEMUtXS1UzNGdQX2dmX3BuMVBPYVJGWFhvRWk3MzBWUE1UZks2ekM2VzZJYnBMMV9JUjBmYU9pdUdycWVuMWE0RWJLZ3N2Wjcwb0ZjMkUyc1JrS3dGRE0zVVJLcHJEanVqSFlIemRSZnZPdzlPQkdGS3lCTXB0Nl80TEZjRU5MSFQ4NFBXM3VYeGk5dTRaZWlHMW05dDVfbWVoWEhzZ3NRNUlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxPcUZwZmJHUVJOd2ZEX3BOVjZCUk9XMmhTZ3R5aE96U3M3TDNjU1FPRThFbTNHd2x0eHF0SnZWSzE4S2ozR3FidFRvSWplSlBRczc5RjBud2F2QTFWRlhvbmNHajFJNWdCUFoxZTY0MTRoTExjS3VpWGRKTU1RTVNRSW43eWk4TFJfQ0UxQ3NJQ3EzX1AtemtjR1Y0SmdBZWo4aVdFbGpseWZmZTRfTi1BOEhfWC15cFljR2ZJQmx6ZXZ5d3FuSHBNNWxGWnRoQjgzcVlJSGllLV9VRXJtM2hSS01VNi1GQzhNNUdQWDJFQ2tLek03Ylo3MXB3bXlGSzFMYi13bUNISzN4dVhzN3prTllOSW4tbFc2Z1l3UWVqTW9KXzJKWk5Fby1pZUxBMko5b3BiTVlBbVhZbFNfV0lSN1VhbmJxMlVWNW9MaQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNaDE1X3RtSGVvXzlkT1l5WkxjdFpVNGJIWlA4alhqZDVpX2I0MDVUbVpHSVBUZGhvUDNoSXlVNVlfdUhaOTZFcmR3d0VyeENEQ0liZTJveU9GRXFQTGJHdWJIeE5WeE1wTXBGNi15LW9TX3VLWkJfaTU0eG9xdlU1TTlQeWVKdFBTWDgzdkdxZUpXT0ZFTXZPZXFwd1ZPdEFWclNZTXFxcGZaTHFKZ0Z1VVdNS1l4UVNhbHJDLWY1cEZqQQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaDJWWUpKakk4NE9YRmJFUjY3ZkNHM2J1X055eUxqeUtUSnVoOWhNbWpvTkNKbm9GQ0U4NE1DbThFUU8wYmNrM0tNbkdRR0FpMHVfM2tKOXhuOExNQU1ZQkxrQlMybGpsRDJhR0JWTkNfeDdueW5KekZFYVM3cXB4a2xHT28zbDNXcGY5M1k5UGhrSjd3UzczSzY5VW9qUU9YWExHRVBHUkNjRGllN05EdmJLZWFfeHZ6REhV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNM2llTHRJeGxfMy1jMGdvaWtTaS0wamY0NC1nalpURGdFQWFfVm1SM3JhdlB1ZVFUc3VGQlUzaWRTQjBXbi1UV24wOXI2S2VJR19LdklvVW9YZEprY2JHU0RVdUtGZm5iSG5neDNoTjFYdWxCTTBzTEJVVDl6WVc4VS1UQ0toQXpxbTF0TGlScUVRS2kteVFHaUR0UmR2S1BOeVRZNGhMTXllRDBkT0R6SDBFQXRKQU9YYUlvN2xBbURLdUVlV1JWR0plNG9hdU52WW02bTlHOThMcFE3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPLTRDY3lyc2kzV2Z6VnhmYlhSbkNFVUhQSVVSWmRUM0xOWXBkNWplMmNub2tPY3NzeDZoZXN1eVZUTnJaUU9WNW5qMVRhUnFqcXVLZzVWZUtyTmMxZFN6U1dKN0dVY0N1T0VQRGowUk9lbjZfTUdTTkVCV1d2ZWFJOVRWZHltM2RWQV9oVXByTzRNcmtDNmhhc2ZQZ2ROYjJlNksyODZ0V3YwTWFzeUdkSVZ5bUZVRUc4WkhOY2RYNA?oc=5", "source_name": "TradingView", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQaC1OZW5wb09uaEl4M0V6azVLUURNdUYybWFOTjVETUU4Q3VOTmtITWNCa3k0c0dxa1RkLWFYa2EtdGZrNmMyem9hZnZZMkZxczJxOFVMUzJYOU1KWi0yX2ZnY0lKaTRLU0pELUpqbzBNT1lpYjFKeEtVMXAyUGQyMGJLcnRXQUtTcmFMaW5sb05FT2NmNWwxVDVSTWNnLUJxWGdBWlhQMjQ4X196SklwaA?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EWTX Stock Hits Record High \u2013 Why Servier Is Shelling Out $2.65B For Edgewise\u2019s Muscular Dystrophy Business", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNdW13cWI3aWtGeFN1ZkYxSUF2TU1ScGNCMEY5RDlnd3dyRjJIT0FjeVRTNGstWUFPT1lSMlNzTnFhQ0JiM2lKbWt0VlFuQlhSQl9HN0VnUzNPU1NiV1hCc3htdW5xNUZZVEVGMWNXUHNZczBSaXJQbFl4SXI0LUpPXzFQd2V4V0ZCQW5JNHdGeDhKMHNRMHdMN21NTzlJWHQwY281U3RreF8ySEFmcC1NSA?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdUNKRVpMMldfSXBFVjNDaHZ1QzU1c3ZmSjVYQl9zV1Y4aTZGeExTbWROU0dTNjZuS2ZiWU1DQUs5X3lBcEhiU0Fvc2liMkREdmtOY2VsaFpZb09pV3h2d2NxelBEQUZ4eTM3T2d5MnhfMmtNdGFVVVBXZ2J5b3hiMUJVUmYwUHVOUmJMcTBzalhwdDdtbFRPcGIwbXhMVUVtakpSSG5sWHdHWDEzaEd5YVhFZmc5Q3BpU0w5QkwySHNPcUd4NWZTalFB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Muscular dystrophy sale to bring Edgewise $1.55B for heart drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaDZJajFETm1CNkd6M0lJZjdzak0xS0JoSXFGN0RndUZVVy05VGxEa1o2R0wxTEVSWGVMY245akpVdHg2VWF0cWJhSVM4TzI3MFFZclJpazVaNjRZRUNsdG9UaUpudlA4Uk9KNEpLUS05MUYxbndHMlozVUtSU3lQNm9xU2tIYVI4ZlpaTXFFWml6Nld3RTJ3OGRIbDJBZ21YV3I4aURUNjhXczRqWnZ5MTk2UnVFWkRXSHMwTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQNElUSWVkT0lKNkN0Zkk3dDltanFTMTdBeS1BTDVkeG1Xb3c5elpKOWRaVGlhZ25YTFNKOEU0RXhWZGhrN2ZEUXoyWHdhaFVPRWl5N2t3OS1EZEt0blh0VU9qbTJfdWhneFVXX3hVZHlsTmlObnFDQkRWR3R3NzBoWnhqdHpEWEEyM05JdWxPRWtxSVFZLVpWdG1DZUN4Y2pfUTRyakxvOHpsQ1BqQzNXZWw0U24?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNck9HQ3o3S1lyZ0IyVl9CRWRtVEhzdXhrbjFxMFVTVHI0MHI3RGJOQVB3LUFpay1vTVZjTHhWZERWa1UyeHJCOWE3dEZQeC1HVXgwLUxXNmZTN0M1dmppdy1sMU5uZTMxZGFaMm1FRG1KMWpWb1hraldraTNOVFpGQlhfLVlyX3pXTGxBbHRLMnNRNlBzOW50b1VrQXdadlRhc2NOMks3UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome \u2013 So, Why Are Analysts Bullish On Edgewise Therapeutics?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQLVpXdWp1VUhQdTJwbjB3Z2l5NlBtQXZ0Rk1IYkcwMlZGeDVIVXVxNlY4NjA0alJuRTNLZEdVVFQ2bFA5SlkxUmpWWXJHTW1XeUlZbC1aZnFsdG5KUW1aT1JlcFRHY3NrRWNZT1g0WkhKWEpfc2NMRDRkX3llRXhIT2ttbmYyZ0kwT18wc0VacnhldWZNdzQwTUlfUW56VVhvSnpFcFlfNm9zX29TZ2hj?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Edgewise Therapeutics Stock Topped the Market on Tuesday", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOVHJSV1RRc2hSaURqbWlBWS16NVlnWjZzWDFCNHV2OUowMjNxVk5reS1qY1ZMMW44V2RRTVVKcndmNlQzOTVTRk85ZVI2NDFkLUZtQXJkSGk5dWRGbWR3RE13cVhodzVvaWN3MUJsb1BSaHBOT21zbzg0dWN2ZUhNUFd4d0dWOG5ZREFuVUd5NXFGek56TGVv?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxOeVZfa01UU1p1b0VsaXBtQ0tnSzFTenZlQkI0TlVXMGxmVE90QWVuVG45cTFnLUNwWkY4RGtPdHl0YkIyREwwZGJnN0F4cnFRZFc1S0lPbWZyREk3M2szT1hEWVJtaXJjSVRWVGJtS2NJbXQwSG9LU3FiVWpoZk9YNVNCQlpuRUR6VXBjSUpxUURxNE5ES0c1M3k5LWhEMzRIUHNuVmxGS20wT1h6STVUTEJXdDk0dUVCeW0wdFk2bXZuX0RVZDZuX2J3VjdiUzhiQzdfUjdBR19LdUxIMWZuU2sxYk1YR2hqQjQ1NVdnc1pibVJJOUZWc1kyN1ZpX1ktbmRYMVRPREFiQmtRVm1qSmxMVFN4NlhSM1lqTzRTNUd2WE1oQ240dERGbjFHWEVHUjNXRG1Wbw?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities \u2013 And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNYnJyUDNLdWZKWk5YeUgyWXhmQnRzbmVqbFl4dVp4MnRyYTM4VTcyYndBRjRDR05SZVFzazlMMXlfWnN3Y3pwVmQ3dVd4bkhBR2NMMHlidWJLVFB4czU2OUx2V2ZtS2YxRDQ5YXprVGt3SFo1Yk85UUlwaktpRUNyVFZuYzU?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease \u2014 Wall Street Eyes A Potential Standout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNYzV0VTZCU25rUzVxeXVnWDF5a1F5MjNRUjNSRWg4UkdFVzE2a0tvYWRhcUZBZEhBZGgycjY0RTlTM21pWktIc2otaXhlTTlWeEpOY3NNanlLZHg0QlYtUVJGNEVDZjhMMW5IUkpTMkdodnQ0WDlGeng0dEYtaXFSZjhhb3pXeFdIR3pXUUh1U2daTUphVzFwWFpudGhMR2NXNmotcTFUeWZ6QlZHSDBITFB4NnZ4Q2lpYlllQkpnQ3FtYlR5d05TRE9Pcnp1TXhBZi1NYUNFU21JQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 47, "sentiment_summary": {"positive": 13, "negative": 3, "neutral": 31, "score": 54, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 45.41, "latest_week": "2026-07-10", "one_week_move": 14.8, "four_week_move": 30.4, "twelve_week_move": 31.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.22907, "market_dynamics_buy_signal": false, "relative_strength": 55.388572, "fair_value_gap": 124.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.5974, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+14.8% over one week, +30.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 10}, {"label": "PR Newswire", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stocktwits", "count": 3}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 10}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+14.8% over one week, +30.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development"}], "updated_at": "2026-07-16T05:41:42.906125+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}